Today: 29 April 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

Scholar Rock shares fell 3.2% to $43.76 Tuesday afternoon, underperforming biotech peers as investors watched for updates on FDA reinspection timing for its lead drug, apitegromab. The company aims to resubmit its biologics license application in 2026 after the Indiana fill-finish site, now owned by Novo Nordisk, completes remediation and is reinspected by year-end 2025.
30 December 2025
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions shares dropped 3.5% to $10.02 in thin year-end trading Tuesday, underperforming a steady U.S. market. The decline followed Federal Reserve minutes showing policy divisions and came as investors awaited January jobs and inflation data. Trading volume in TIC lagged its recent average, and peers Mistras Group and Jacobs Solutions slipped less than 1%.
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries shares fell 3.9% to $8.90 Tuesday after early gains, trading between $8.90 and $9.39. The drop followed news that CEO Lewis Black met U.S. officials and signed a deal tied to future tungsten supply from the Sangdong mine in South Korea, which is set to start production in early 2026. Almonty recently raised $129.4 million in a U.S. share sale and delivered its first ore to Sangdong’s staging area.
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
Why Caris Life Sciences (CAI) stock is down today as biotech slips

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Caris Life Sciences shares fell 1.8% to $27.44 by 2:41 p.m. ET Tuesday, underperforming biotech peers as sector benchmarks declined. The drop followed recent attention on Caris’ Genentech partnership, which includes $25 million upfront and up to $1.1 billion in potential milestones. The S&P 500 and Nasdaq were flat. Investors are watching Caris’ test volumes and revenue guidance.
30 December 2025
Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management shares dropped 3.1% to $163.85 Tuesday afternoon, underperforming rivals as fresh Federal Reserve minutes showed policymakers split on future rate cuts. A Reuters column noted shrinking yield premiums in private credit, a core Ares business, as public markets regain ground. About 966,000 Ares shares traded, with the stock hitting a low of $163.49. Blackstone was flat; Apollo, KKR, and Carlyle edged down less than 1%.
Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Why Karman Holdings Stock Is Down Today: KRMN Slides as Year-End Flows Hit Defense-Space Names

Karman Holdings shares fell 3.6% to $74.81 in New York afternoon trading Tuesday, underperforming the broader market after a $258.7 million outflow from the SPDR S&P Aerospace & Defense ETF. The stock touched a session low of $74.21, with about 465,000 shares traded. Investors are watching for signs of stabilization ahead of the company’s next quarterly update.
1 336 337 338 339 340 584

Stock Market Today

  • Consumer interest rates and inflation shifts under Jerome Powell's Fed tenure
    April 29, 2026, 4:15 PM EDT. During Jerome Powell's eight-year leadership of the Federal Reserve, consumer interest rates and inflation saw notable changes. The Fed increased the key overnight lending rate 15 times and lowered it 11 times, moving the rate from near zero during the pandemic to a peak of 5.25%-5.50% in mid-2023 to counter inflation. Consumer prices rose 32%, with something costing $1,000 in 2018 priced at $1,323 in 2024. Online high-yield savings accounts improved yields from 1.53% in 2018 to an average of 3.43% this year, with top offers at 4.2%-4.4%. The Federal Open Market Committee balances economic data, geopolitical and fiscal factors when setting rates that affect savings returns, borrowing costs, and consumer prices.

Latest article

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

29 April 2026
Vita Coco shares jumped 27% Wednesday after first-quarter net sales rose 37% to $180 million, beating analyst expectations. The company raised its 2026 revenue outlook to $720–$735 million and lifted adjusted EBITDA guidance. Diluted earnings reached $0.50 per share, up from $0.31 a year earlier. Gross margin improved to 39.9% despite higher logistics and tariff costs.
Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

29 April 2026
Marathon Petroleum shares rose 3.2% to $240.05 Wednesday as investors anticipated its May 5 earnings report, following a surge in fuel margins during the first quarter. Phillips 66 and Valero also gained after posting stronger-than-expected results. Marathon’s Robinson refinery in Illinois began planned maintenance in March. U.S. gasoline prices hit $4.18 a gallon, the highest since 2022, according to AAA.
Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

29 April 2026
MaxLinear shares rose about 34% to $69.58 on Wednesday after Loop Capital upgraded the stock and raised its target to $75. The surge followed a first-quarter report showing infrastructure revenue up 136% to become the company’s largest segment. Total revenue climbed 43% to $137.2 million. MaxLinear guided second-quarter revenue to $160–$170 million, citing strong demand for data-center optical products.
Go toTop